20 years of Cure Parkinson's
We’re here for the cure! This year marks 20 years since Cure Parkinson’s was founded by four people living with Parkinson’s who felt that nobody was taking a cure seriously enough and that there was an urgent need for a focused approach to curative research...
Learn more
Results of FAIRPARK-II deferiprone trial published
The results of the most recent study of deferiprone in people with Parkinson’s (the FAIRPARK-II study) have been published in the New England Journal of Medicine.
Rounds for Research
This summer, we’re asking you to complete 2, 4 or 5.5 rounds of golf (or 36, 72 or 100 holes) in one day to raise funds and awareness for our research. You can choose any day to play, just remember that you’ll need all the...
Cure Parkinson’s runners head across the pond for the 2022 New York City Marathon
Four inspirational runners joined Team Cure at the New York City Marathon to raise funds for Parkinson’s research. On Sunday 6 November Cure Parkinson’s CEO Will Cook, Nicky Edwards and brother and sister duo Charlie and Jessica Brew all took part in the iconic race,…
Cure Parkinson’s supporter tackles 100 of Britain’s toughest cycling climbs
Steve Boote cycled 3833km and climbed an astounding 69219m to raise funds and awareness for our research. Steve, a keen cyclist from Steeple Aston, recently completed Britain’s 100 greatest cycling climbs challenge to raise funds and awareness for Cure Parkinson’s. This is the third time…
Disease modification-ish
Semantics matters – particularly regarding our communication on ideas like “disease modification” for neurodegenerative conditions. There is a big difference between “disease eradication” (zero worldwide incidence), “disease correction” (the halting/reversing of progression) and “disease modification” (improving the trajectory of disease). Recently, researchers in Japan have demonstrated “disease modification” in motor neuron […]